The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …

Background Although the development of BCR:: ABL1 tyrosine kinase inhibitors (TKIs)
rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug …

A total of 156 patients (age range 1.3–18.0 years, median 13.2 years; 91 (58.3%) male) with
newly diagnosed CML (N= 146 chronic phase (CML-CP), N= 3 accelerated phase (CML …

In this provocative commentary, we consider several questions posed by the late chronic
myeloid leukaemia (CML) expert Prof. Michele Baccarani, which he challenged us to …

Simple Summary This review explores the use of hematopoietic stem cell transplantation
(HSCT) as a treatment option for chronic myeloid leukemia (CML) patients. While CML …

Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of
patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic …

In addition to the best possible overall survival, discontinuation of the tyrosine kinase‐
inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of …

There are no validated molecular biomarkers to identify newly-diagnosed individuals with
chronic-phase chronic myeloid leukemia likely to respond poorly to imatinib and who might …

The remarkable clinical activity of tyrosine kinase inhibitors (TKIs) in chronic myeloid
leukemia (CML) has transformed patient outcome. Consequently, allogeneic stem cell …